Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
On June 23, 2026, Sangamo announced that it has entered into asset sale agreements with Lilly and Astellas and commenced a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders. To learn more, visit https://www.veritaglobal.net/SangamoTherapeutics.
Minimum 15 minutes delayed. Source: LSEG
